Prof Halfdan Sorbye
Professor and Head of NET and GI section at Department of Oncology, Haukeland University Hospital, Bergen, Norway. He has a major research focus on Gastroenteropancreatic (GEP) Neuroendocrine carcinoma (NEC), Neuroendocrine Tumors (NET) and metastatic colorectal cancer and also 100 peer review publications, 3330 citations. The landmark study Nordic NEC in 2013 showed for the first time that the GEP WHO G3 group was a very heterogeneous group both concerning prognosis and with regard to response to chemotherapy. He is also a member of the ENETS advisory board, a faculty member for Endocrine Tumors and Gastro-Intestinal Tumors for ESMO (European Society of Medical Oncology) and executive Board for Nordic Neuroendocrine Tumor Group.
His most relevant publications:
The NORDIC NEC study. Ann Oncol 2013, 24: 152-160. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer 2014, 120: 2814-23, High-grade gastroenteropancreatic neuroendocrine carcinoma. UpToDate, 2018, Unmet needs in high-grade GEP neuroendocrine neoplasms (WHO G3). Neuroendocrinology 2018.